Opaleye Management Inc.
SEC Form 4 insider transaction history, cleaned and classified by FilingIQ.
Total trades
292
Last 180 days
84
Last trade
Oct 12, 2026
Recent tickers traded
Latest filings by Opaleye Management Inc.
GRCE Grace Therapeutics, Inc.
P Oct 12, 2026
GRCE Grace Therapeutics, Inc.
P Oct 1, 2026
ACOG Alpha Cognition Inc.
P Oct 1, 2026
GRCE Grace Therapeutics, Inc.
P Sep 29, 2026
ACOG Alpha Cognition Inc.
P Sep 24, 2026
Most recent disclosures. Sign up to filter by transaction code, company or dollar value.
Activity overview
FilingIQ has indexed 292 SEC Form 4 insider transactions associated with Opaleye Management Inc.. The most recent transaction is dated Oct 12, 2026.
Frequently asked
- How many Form 4 transactions has Opaleye Management Inc. filed?
- FilingIQ has indexed 292 SEC Form 4 insider transactions associated with Opaleye Management Inc.. The most recent transaction is dated Oct 12, 2026. Every filing sources back directly to SEC EDGAR.
- What does FilingIQ show for Opaleye Management Inc.'s trades?
- Each open-market purchase and sale carries the same seven facts: its size in Opaleye Management Inc.'s own history at that company, the change in holdings, the previous trade, other insiders at the company in the 30 days before, the Rule 10b5-1 plan answer, the reporting time and other companies. FilingIQ does not rate the trades. The rules are at /methodology.
- Which companies has Opaleye Management Inc. traded?
- Most recent trading activity covers ACOG, CDXS, ETON, GRCE, HROW. The full Form 4 history including older issuers is available on the FilingIQ web app.
- Where does FilingIQ's insider data come from?
- Every Form 4 transaction shown on this page is parsed directly from SEC EDGAR XML filings. Insider identity is normalized across CIK changes, name spellings, and indirect / related-party reporting.
Methodology & sources
All Form 4 transactions parsed directly from public SEC EDGAR XML filings. How lines are classified and which facts FilingIQ adds is documented on methodology. Compiled by Thomas Kraaibeek. Not investment advice; see disclaimer.